PAR 2.17% 23.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-1647

  1. 318 Posts.
    lightbulb Created with Sketch. 37
    I agree. However I feel that it may not be PAR who receives the final approval. it will more than likely be a big Pharma who will obtain it probably easier than we would.
    We will all reap great rewards and more importantly the treatment will be available to all
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.